Pfizer Corporation

Wyeth

Katherine Lin Lee

Lihren Chen

John C McKew

James D Clark

Christoph Martin Dehnhardt

Joseph Walter Strohbach

Eddine Saiah

David Hepworth

Christoph Wolfgang Zapf

Nikolaos Papaioannou

Arthur Lee

Stephen Wayne Wright

Frank Eldridge Lovering

John David Trzupek

Richard Vargas

Seungil Han

Lori Krim Gavrin

Fuk-Wah Sum

John Paul Mathias

Mark L Behnke

Baihua Hu

Paresh Thakker

Akshay Patny

Kevin Joseph Curran

Xiaolun Wang

Joel A Goldberg

Michael Dennis Lowe

David R Anderson

Mark Edward Bunnage

Horng-Chih Huang

Betsy Susan Pierce

Kevin Pong

Steven Y Tam

Valerie Clerin

Suzana Marusic

Wei Li

Steve Yikkai Tam

Dafydd Rhys Owen

Christophe Philippe Allais

Cara Williams

Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. In an embodiment, a pharmaceutical composition can be in a liquid dosage form and can comprise a therapeutically effective amount of the compound or a pharmaceutically acceptable salt thereof as an adjuvant and a therapeutic agent. In another embodiment, a method of adjuvant treating a disorder or condition can comprising administering the pharmaceutical composition to a patient.

Bicyclic-fused heteroaryl or aryl compounds

Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Bicyclic-fused heteroaryl or aryl compounds as IRAK4 modulators

Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed. 

This invention provides chemical inhibitors of the activity of various phospholipase enzymes, particularly cytosolic phospholipase Aenzymes (cPLA), more particularly including inhibitors of cytosolic phospholipase Aalpha enzymes (cPLA&#x3b1;). In some embodiments, the inhibitors have the Formula I: wherein the constituent variables are as defined herein.

[object Object]

This invention provides methods for the use of substituted indole compounds of the general formula: and pharmaceutically acceptable salt forms thereof. The invention provides methods for the use of the compounds as inhibitors of the activity of various phospholipase enzymes, particularly phospholipase Aenzymes, and for the medical treatment, prevention and inhibition diseases and disorders including asthma, stroke, atherosclerosis, multiple sclerosis, Parkinson's disease, arthritic disorders, rheumatic disorders, central nervous system damage resulting from stroke, central nervous system damage resulting from ischemia, central nervous system damage resulting from trauma, inflammation caused or potentiated by prostaglandins, inflammation caused or potentiated by leukotrienes, inflammation caused or potentiated by platelet activation factor, pain caused or potentiated by prostaglandins, pain caused or potentiated by leukotrienes, and pain caused or potentiated by platelet activation factor.

Methods for the use of inhibitors of cytosolic phospholipase A2

This invention provides methods for treating in mammals asthma and asthmatic conditions using substituted indole compounds of the general formula: and pharmaceutically acceptable salt forms thereof, and methods for using the compounds as inhibitors of the activity of various phospholipase enzymes, particularly phospholipase Aenzymes, and for the medical treatment, prevention and inhibition of pain and inflammation.

Methods for treating asthmatic conditions

This invention provides methods for treating in mammals arthritic or rheumatic disorders using substituted indole compounds of the general formula: and pharmaceutically acceptable salt forms thereof, and methods for using the compounds as inhibitors of the activity of various phospholipase enzymes, particularly phospholipase Aenzymes, and for the medical treatment, prevention and inhibition of pain and inflammation.

Methods for treating arthritic disorders

A process for making an aromatic aldehyde in which a sulfoxide is reacted with a dihalogenated aromatic compound in the absence of an effective amount of an activating reagent. The aldehyde may then be used to make other compounds, such as a compound that acts as a cPLA inhibitor.

Process for making an aldehyde

Growing community of inventors

West Newton, MA, United States of America

Katherine Lin Lee